Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
出版年份 2022 全文链接
标题
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
作者
关键词
-
出版物
Oncology and Therapy
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-12-13
DOI
10.1007/s40487-022-00212-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
- (2022) José-Ángel Hernández-Rivas et al. Biomarker Research
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- (2022) Maria-Victoria Mateos et al. LEUKEMIA
- Extramedullary disease in multiple myeloma: a systematic literature review
- (2022) Joan Bladé et al. Blood Cancer Journal
- Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
- (2022) Tamir Shragai et al. BRITISH JOURNAL OF HAEMATOLOGY
- Monoclonal Antibodies in Myeloma
- (2021) Monique Hartley-Brown et al. CANCER JOURNAL
- Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting
- (2021) Louise Kostos et al. INTERNATIONAL JOURNAL OF CANCER
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
- (2021) Malin Hultcrantz et al. Clinical Lymphoma Myeloma & Leukemia
- Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
- (2021) Massimo Offidani et al. Drug Design Development and Therapy
- Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
- (2021) Malin Hultcrantz et al. BLOOD
- Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma
- (2021) Tahani Atieh et al. BLOOD
- Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study
- (2021) Sujith Dhanasiri et al. CLINICAL THERAPEUTICS
- “Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
- (2021) I. Vaxman et al. Blood Cancer Journal
- Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
- (2020) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
- (2020) Semira Sheikh et al. Future Oncology
- Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2020
- (2020) Ivo Demel et al. BRITISH JOURNAL OF HAEMATOLOGY
- EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
- (2020) Kyriaki Tzogani et al. ONCOLOGIST
- Treatment Options for Triple-class Refractory Multiple Myeloma
- (2019) Joseph Mikhael Clinical Lymphoma Myeloma & Leukemia
- Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma
- (2019) Ajai Chari et al. Clinical Lymphoma Myeloma & Leukemia
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now